Stay updated with breaking news from Nasdaq Fold. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Wednesday. Amicus Therapeutics Stock Performance Amicus Therapeutics stock traded down $0.12 during mid-day trading on Wednesday, reaching $12.87. The company had a trading volume of 1,633,135 shares, compared […]
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) – Equities research analysts at Cantor Fitzgerald upped their FY2023 earnings per share (EPS) estimates for Amicus Therapeutics in a note issued to investors on Wednesday, August 9th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will earn ($0.44) per share for the year, up […]
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) – Investment analysts at Leerink Partnrs raised their Q3 2023 earnings estimates for Amicus Therapeutics in a research note issued to investors on Tuesday, August 8th. Leerink Partnrs analyst J. Schwartz now expects that the biopharmaceutical company will post earnings per share of ($0.07) for the quarter, up […]
Assetmark Inc. boosted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 19.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 44,658 shares of the biopharmaceutical company’s stock after purchasing an additional 7,152 shares during the period. Assetmark Inc.’s […]
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $14.10 and last traded at $13.74, with a volume of 622787 shares traded. The stock had previously closed at $13.86. Analysts Set New Price Targets Separately, StockNews.com began […]